[go: up one dir, main page]

NO20051561L - Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. - Google Patents

Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.

Info

Publication number
NO20051561L
NO20051561L NO20051561A NO20051561A NO20051561L NO 20051561 L NO20051561 L NO 20051561L NO 20051561 A NO20051561 A NO 20051561A NO 20051561 A NO20051561 A NO 20051561A NO 20051561 L NO20051561 L NO 20051561L
Authority
NO
Norway
Prior art keywords
nucleic acid
acid molecules
human papillomavirus
molecules encoding
vaccine
Prior art date
Application number
NO20051561A
Other languages
English (en)
Other versions
NO20051561D0 (no
Inventor
Gerald Wayne Gough
Christopher Michael Roberts
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20051561D0 publication Critical patent/NO20051561D0/no
Publication of NO20051561L publication Critical patent/NO20051561L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter og preparater egnet ved behandling og forebygging av infeksjoner med humant papillomavims. Spesielt angår oppfinnelsen nukleinsyremolekyler som koder for El og/eller E2 og vektorer egnet for DNA-vaksineavgivelse, og farmasøytiske preparater inneholdende dem. Fremgangsmåter for fremstilling av disse molekyler, vektorer og preparater er også påtenkt.
NO20051561A 2002-10-03 2005-03-23 Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. NO20051561L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222953.2A GB0222953D0 (en) 2002-10-03 2002-10-03 Novel Compounds
PCT/EP2003/011158 WO2004031222A2 (en) 2002-10-03 2003-10-01 Dna vaccine encoding at least two nonstructural early proteins of papillomavirus

Publications (2)

Publication Number Publication Date
NO20051561D0 NO20051561D0 (no) 2005-03-23
NO20051561L true NO20051561L (no) 2005-06-02

Family

ID=9945247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051561A NO20051561L (no) 2002-10-03 2005-03-23 Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.

Country Status (21)

Country Link
US (2) US20060165713A1 (no)
EP (1) EP1546191A2 (no)
JP (1) JP2006516386A (no)
KR (1) KR20050050115A (no)
CN (1) CN100393878C (no)
AR (1) AR041515A1 (no)
AU (1) AU2003294672A1 (no)
BR (1) BR0314986A (no)
CA (1) CA2500093A1 (no)
CO (1) CO5580837A2 (no)
GB (1) GB0222953D0 (no)
IS (1) IS7775A (no)
MA (1) MA27474A1 (no)
MX (1) MXPA05003558A (no)
NO (1) NO20051561L (no)
NZ (1) NZ539154A (no)
PL (1) PL376534A1 (no)
RU (1) RU2354701C2 (no)
TW (1) TW200411055A (no)
WO (1) WO2004031222A2 (no)
ZA (1) ZA200503201B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101948835A (zh) 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
EP2390340A3 (en) * 2007-01-30 2012-02-22 Transgene SA vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
KR20130087517A (ko) 2010-06-25 2013-08-06 백시바디 에이에스 동종이합체 단백질 구조물
IL251825B2 (en) * 2014-10-24 2023-09-01 Hpvvax Llc Treatment of cancer and skin damage
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
WO2017191147A1 (en) * 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
MX2023006038A (es) * 2020-11-25 2023-07-11 Precigen Inc Vacunas contra el virus del papiloma humano y usos de estas para enfermedades asociadas a hpv.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
HK1056195B (en) * 2000-07-21 2007-06-22 Glaxo Group Limited Codon-optimized papilloma virus sequences
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences

Also Published As

Publication number Publication date
US20070264283A1 (en) 2007-11-15
WO2004031222A3 (en) 2004-08-19
BR0314986A (pt) 2005-08-09
US20060165713A1 (en) 2006-07-27
NO20051561D0 (no) 2005-03-23
AR041515A1 (es) 2005-05-18
CO5580837A2 (es) 2005-11-30
JP2006516386A (ja) 2006-07-06
KR20050050115A (ko) 2005-05-27
WO2004031222A2 (en) 2004-04-15
GB0222953D0 (en) 2002-11-13
ZA200503201B (en) 2006-06-28
MXPA05003558A (es) 2005-06-03
PL376534A1 (pl) 2006-01-09
EP1546191A2 (en) 2005-06-29
IS7775A (is) 2005-03-29
AU2003294672A1 (en) 2004-04-23
CA2500093A1 (en) 2004-04-15
CN100393878C (zh) 2008-06-11
CN1720261A (zh) 2006-01-11
MA27474A1 (fr) 2005-08-01
RU2005109155A (ru) 2006-03-10
NZ539154A (en) 2007-05-31
RU2354701C2 (ru) 2009-05-10
TW200411055A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
NO20064584L (no) Tetrahydropyridoindolderivater
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
HUP0402259A2 (hu) Vakcinák
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NZ543467A (en) The severe acute respiratory syndrome coronavirus
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
NO20064059L (no) Albumin fusjonsproteiner
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
NO20055624L (no) Tropanderivater og deres anvendelse som Ace-inhibitorer
WO2009037183A3 (de) Nukleinsäurehaltige kosmetische und/oder pharmazeutische zubereitung zur induktion antimikrobieller peptide in epithelialen deckgeweben
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application